Volume 6, Number 5—October 2000
Dispatch
Double infection with a Resistant and a Multidrug-Resistant Strain of Mycobacterium tuberculosis
Table
Treatment regimens and characteristics of Mycobacterium tuberculosis isolatesa
| Treatment | Therapy | Susceptibility testing | |||||
|---|---|---|---|---|---|---|---|
| Months | Hospital | Regimen | Culture | Culture obtained | Current resistance pattern | Time delay (months)b | Spoligotype |
| 0 | A/B | H, R, E,c Z | pos. | 02/28/96 | H, S | 2 | type I |
| 1 | B | H, R, Z | pos. | 03/17/96 | H, S | 2 | type I |
| 2 | B | H, R, E, Z | neg. | - | - | - | - |
| 3 | B | H, R, E, Z | neg./pos. | - | n.d. | - | n.d. |
| 4 | C | H, E, Pt | pos. | 06/06/96 | H, S, R, (E), (Rb) | 2 | type II |
| 5 | D | R, E, Z | pos. | 07/12/96 | H, S, R, (E), (Rb) | 2 | type II |
| 6 | D | E, Z, Rb, Of | pos. | - | n.d. | - | n.d. |
| 7-12 | D | E, Z, Rb, Pt | pos. | - | n.d. | - | n.d. |
| 13 | D | E, Z, Rb, Pt | pos. | 03/15/97 | H, S, R, E, Rb, Pt | 1 | type II |
| 14-18 | D | Z, Pt, Ci | pos. | 04/25/97 | H, S, R, E, Rb, Pt, Z | 5 | type II |
| 19 | D | Z, Pt, Rb, Ci | pos. | - | n.d. | - | n.d. |
| 20-21 | D | Rb, Ci, Am, Pa | pos. | - | n.d. | - | n.d. |
| 22-24 | D | Rb, Ci, Am, Pa, Cl | pos. | - | n.d. | - | n.d. |
| 25-28 | D | Rb, Ci, Am, Pa, Cl | pos./neg. | 02/18/98 | H, S, R, E, Rb, Pt Z, Pa | 4 | type II |
| 29-32 | D | Rb, Ci, Am, Pa, Cl | pos. | 06/23/98 | H, S, R, E, Rb, Pt, Z, Pa, Am | 4 | type II |
| 33 | D | Rb, Ci, Cl, Ca | pos. | - | n.d. | - | n.d. |
aAbbreviations and symbols: H, isoniazid; S, streptomycin; R, rifampin; E, ethambutol; Rb, rifabutin; Pt, protionamide; Z, pyrazinamide; Pa, p=aminosalicylic acid; Am, amikacin; Of, ofloxacin, Ci, ciprofloxacin; Cl, clofazimine; Ca, capreomycin; borderline results are shown in parentheses; pos., positive culture result; neg., negative culture result; n.d., not determined.
b Time between the date on which the specimen was obtained and the date on which the drug-susceptibility pattern was available for the clinician (drug-susceptibility testings were not always performed directly after the cultures were grown but were done retrospectively).
cE was given in the first 4 days of therapy only.